We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The approval of Novartis’ novel gene therapy Zolgensma was one of CBER’s major achievements in fiscal 2019, according to center Director Peter Marks. Read More
Drug imports to the U.S from Canada “will have little or no impact on U.S. drug prices,” and will cause problems for Canadians, according to Canada’s acting Ambassador to the U.S., Kirsten Hillman. Read More